RESEARCH COMMONS
LIBRARY

The Market Return To Pharmaceutical Product Approval

ResearchCommons/Manakin Repository

The Market Return To Pharmaceutical Product Approval

Show simple item record

dc.contributor.author Ahmed, Imtiaz en_US
dc.date.accessioned 2007-08-23T01:56:35Z
dc.date.available 2007-08-23T01:56:35Z
dc.date.issued 2007-08-23T01:56:35Z
dc.date.submitted May 2007 en_US
dc.identifier.other DISS-1730 en_US
dc.identifier.uri http://hdl.handle.net/10106/380
dc.description.abstract Does the public announcement of approval of New Drugs affect the market valuation of the sponsoring pharmaceutical company? This study will try to find out the technically and intuitively acceptable answer of this question using event study methodology. Relatively smaller number of previous studies on this issue found the mixed answers of this question using well-tested methodology of event study. Basing on the notion that the Efficient Market Hypothesis (EMH) is in effect in the pharmaceutical industry, stock and securities market should ideally react quickly (i.e., efficiently) in response to the public announcement of approval of new drug by the Food and Drug Administration (FDA) and the positive abnormal return may be expected for the sponsoring pharmaceutical company on and around the event date i.e., the day of the public announcement of the new drug approval for marketing. Using the OLS and the 2SLS to carry-out the event study for four-hundred events of eleven pharmaceutical companies ranging twenty-three years, this study has found the mixed outcomes similar to some of the previous studies on this issue. Briefly, the findings of the present study are: (a) Existence of statistically significant positive abnormal returns (AR) for the day following the events. (b) The cumulative abnormal return (CAR) is statistically insignificant for the estimates of the pooled regressions and for some of the individual pharmaceutical companies. (c) No sign of information leakage ahead of the events. (d) Some individual pharmaceutical companies show the existence of statistically significant positive abnormal returns (AR) and the cumulative abnormal return (CAR) for event day and the day after (e.g. Novartis, Abbott). The technical reasons and the intuitive explanations behind these findings will be revealed in the analysis of empirical results and in the concluding remarks of this study. en_US
dc.description.sponsorship Ward, Michael en_US
dc.language.iso EN en_US
dc.publisher Economics en_US
dc.title The Market Return To Pharmaceutical Product Approval en_US
dc.type M.A. en_US
dc.contributor.committeeChair Ward, Michael en_US
dc.degree.department Economics en_US
dc.degree.discipline Economics en_US
dc.degree.grantor University of Texas at Arlington en_US
dc.degree.level masters en_US
dc.degree.name M.A. en_US
dc.identifier.externalLink https://www.uta.edu/ra/real/editprofile.php?onlyview=1&pid=2115
dc.identifier.externalLinkDescription Link to Research Profiles

Files in this item

Files Size Format View
umi-uta-1730.pdf 502.7Kb PDF View/Open
502.7Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

Browse

My Account

Statistics

About Us